Show simple record

dc.contributor.authorVyas, Madhusudan
dc.date.accessioned2022-09-29T21:44:41Z
dc.date.available2022-09-29T21:44:41Z
dc.date.issued2022-07-23
dc.identifier.urihttps://hdl.handle.net/10652/5803
dc.description.abstractOBJECTIVES To assess the efficacy of Lutetium-177-PSMA-I&T therapy to palliate end stage mCRPC To review tolerability and impact on QOL of Lutetium-177- PSMA-I&T therapyen_NZ
dc.language.isoenen_NZ
dc.rightsAll rights reserveden_NZ
dc.subjectNew Zealanden_NZ
dc.subjectcancer patientsen_NZ
dc.subjectprostate canceren_NZ
dc.subjecttheranosticsen_NZ
dc.subjectradionuclide therapyen_NZ
dc.subjectLu-177en_NZ
dc.subjectLutetium-177en_NZ
dc.subjectneuroendocrine tumours (NETs)en_NZ
dc.subjectmetastatic castration-resistant prostate cancer (mCRPC)en_NZ
dc.subjectmCRPCen_NZ
dc.titleA first NZ study looked at the role of Lutetium-177-PSMA I & T in the progression of mCRPCen_NZ
dc.typeConference Contribution - Oral Presentationen_NZ
dc.date.updated2022-09-29T13:30:07Z
dc.rights.holderAuthoren_NZ
dc.subject.marsden3211 Oncology and carcinogenesisen_NZ
dc.subject.marsden320215 Nuclear medicineen_NZ
dc.identifier.bibliographicCitationVyas, Madhusudan. (2022, July). A first NZ Study Looked at the Role of Lutetium-177-PSMA I & T in the Progression of mCRPC. Paper presented at the Auckland/Northland Branch NZIMRT, Auckland University Medical School, Auckland.en_NZ
unitec.publication.titleAuckland/Northland Branch NZIMRTen_NZ
unitec.conference.titleAuckland/Northland Branch NZIMRT Study Day (2022)en_NZ
unitec.conference.orgNew Zealand Institute of Medication Radiation Technology (NZIMRT)en_NZ
unitec.conference.locationAuckland University Medical School, Aucklanden_NZ
unitec.conference.sdate2022-07-23
unitec.conference.edate2022-07-23
unitec.peerreviewedyesen_NZ
dc.contributor.affiliationUnitec Institute of Technologyen_NZ
unitec.identifier.roms68787en_NZ
unitec.institution.studyareaHealth Sciencesen_NZ


Files in this item

Thumbnail

This item appears in

Show simple record